March 18, 2020 —

Eurofins is committed to supporting physicians in providing optimal care for their transplant patients. With the outbreak of COVID-19, we understand that transplant programs are minimizing office visits, both to ensure patient health and safety, as well as reduce the burden on staff so they may focus their care on patients who are most in need.

To help physicians continue to provide state-of-the-art care for their patients without requiring them to visit the transplant center, Eurofins Transplant Genomics and Eurofins Viracor have partnered to offer a comprehensive catalog of tests – all of which can be run from samples collected remotely. Of particular note, our testing services include:

– TruGraf: the only blood test approved by CMS for surveillance to rule out silent rejection in stable kidney transplant recipients and provide comfort that patients are likely to be immune quiescent (via Transplant Genomics)

– TRAC: to analyze donor-derived cell-free-DNA levels in blood to rule out rejection in patients suspected of rejecting (via Viracor)

In addition, Eurofins Viracor is now offering testing for SARS-CoV-2 in kidney transplant donors and recipients.

For information on ordering tests and arranging remote sample collection, physicians may contact us directly at 1-844-TruGraf or (800) 305-5198 for Eurofins Viracor Client Services. You may also visit our websites at www.trugraf.com, Viracor-Eurofins.com/TRAC and Viracor-Eurofins.com/Coronavirus.

Thank you for putting your trust in us during this difficult period.

Sincerely yours,

CEO
Eurofins Transplant Genomics
Stanley D. Rose, Ph.D.